Shield's oral Feraccru non-inferior to IV Injectafer in Phase IIIb

Shield said oral Feraccru ferric maltol met the primary endpoint of non-inferiority to IV Injectafer ferric carboxymaltose

Read the full 172 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE